Monotherapy of commonly used anti-hyperglycemic agents (AHA) for the treatment of type 2 diabetes mellitus (T2DM): patient characteristics and time to addition of subsequent therapy (augmentation).

156.

  • Martin, Silas MS
  • Burke, James Ph.D.
  • Neslusan, Cheryl Ph.D.
  • Johnson, Jonathan MS
  • Bailey, Robert M.D.

  • (1) Health Economics and Outcomes Research, Janssen Scientific Affairs, LLC, Raritan, NJ (2) Health Economics and Outcomes Research, OptumInsight, Eden Prairie, MN (3) Global Strategic Marketing and Market Access, Janssen Global Services, LLC, Raritan, NJ (4) Janssen Scientific Affairs, LLC, Raritan, NJ

Pharmacotherapy: The Journal Of Human Pharmacology & Drug Therapy 33(10):p e229, October 2013.
Copyright © 1999?2012 John Wiley & Sons, Inc
View full text|Download PDF